samedan logo
 
 
 
spacer
home > ebr > summer 2019 > mass spectrometric analysis of process-related impurities
PUBLICATIONS
European Biopharmaceutical Review

Mass Spectrometric Analysis of Process-Related Impurities

The production process of any biological drug requires the use of a wide range of chemicals, such as nutrient media, initiators of protein production, selection processes (eg, antibiotics), and chemicals used in the subsequent purification processes. Furthermore, any chemical modifications to the naturally produced biologic, such as PEGylation, will result in an even larger number of chemicals coming into contact with the drug product. All of these extraneous chemicals can end up in small amounts in the final product (despite the significant purification strategies applied during downstream processing) and may be capable of generating a biological response such as an immune reaction or other adverse event in a patient, therefore putting them at risk. Moreover, the product itself may be at risk from extended exposure to these chemicals, such as increased levels of oxidation or aggregation or other chemical modification. Changes to the structure of the product as a result of the action of these residual levels of chemicals can lead to decreased shelf life, increase in aggregation, or other adverse effects, ultimately resulting in a loss of efficacy.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Richard L Easton obtained his PhD in glycoprotein structural characterisation using mass spectrometry from Imperial College of Science, Technology, and Medicine, UK. He subsequently spent several years there as a postdoctoral Research Scientist, working in the field of glycoprotein structural characterisation with emphasis on glycan elucidation. Richard moved to GlaxoSmithKline for a short time where he was Head of Mass Spectrometry for the toxicoproteomics and safety assessment group. He joined M-Scan (now part of SGS Life Sciences) as a Biochemist and became the Team Leader for carbohydrate analysis before being appointed Principal Scientist. Richard joined BioPharmaSpec in 2016 as Technical Director for Structural Analysis and is responsible for management of all aspects of carbohydrate and glycoprotein characterisation at the primary structure level.

Dr Andrew J Reason is the founder, CEO, and Managing Director at BioPharmaSpec. He has 25 years of experience in analysis of both novel and biosimilar biopharmaceuticals and has been involved in the commercialisation of a number of analytical methods for characterising proteins. In addition to his scientific and managerial duties, Andrew has contributed to many industry publications and is a regular presenter at conferences. He is also currently a Visiting Professor at the University of Warwick, UK.
spacer
Dr Richard L Easton
spacer
spacer
spacer
Dr Andrew J Reason
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

European Commission Approves BYANNLIŽ (6-monthly Paliperidone Palmitate; PP6M) for the Maintenance Treatment of Schizophrenia in Adults

 BYANNLIŽ (6-monthly paliperidone palmitate; PP6M) is the first long-acting injectable schizophrenia treatment to be approved with a twice-yearly dosing regimen[1] . The approval is based on results from the Route 6 Study, which showed that 92.5 percent of patients treated with PP6M were relapse-free at the end of the 12-month double-blind phase1.  
More info >>

White Papers

CRSF Label - Child-Resistant Blister Packs With Booklet Label

Faubel & Co. Nachfolger GmbH

This case study explains how Faubel was commissioned by a leading global pharmaceutical company to develop a label for an aluminum blister pack with 14 cavities, which was used as part of a multinational clinical trial. This label was intended to both protect infants from erroneous ingestion and facilitate use by seniors.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement